Fulminant corticobasal degeneration: Agrypnia excitata in corticobasal syndrome

Federico Rodriguez-Porcel; Lindsey Lowder; Rosa Rademakers; Thomas Ravenscroft; Bernardino Ghetti; Mathew C. Hagen; Alberto J. Espay

doi:10.1212/WNL.0000000000002491

Fulminant corticobasal degeneration: Agrypnia excitata in corticobasal syndrome

Federico Rodriguez-Porcel, Lindsey Lowder, Rosa Rademakers, Thomas Ravenscroft, Bernardino Ghetti, Mathew C. Hagen, Alberto J. Espay

Neuroscience

Research output: Contribution to journal › Article › peer-review

6 Scopus citations

Original language	English (US)
Pages (from-to)	1164-1166
Number of pages	3
Journal	Neurology
Volume	86
Issue number	12
DOIs	https://doi.org/10.1212/WNL.0000000000002491
State	Published - Mar 22 2016

ASJC Scopus subject areas

Clinical Neurology

Access to Document

10.1212/WNL.0000000000002491

Cite this

@article{58a44d8657fe426e9fa5138d4e5b980a,

title = "Fulminant corticobasal degeneration: Agrypnia excitata in corticobasal syndrome",

author = "Federico Rodriguez-Porcel and Lindsey Lowder and Rosa Rademakers and Thomas Ravenscroft and Bernardino Ghetti and Hagen, {Mathew C.} and Espay, {Alberto J.}",

note = "Funding Information: Disclosure: F. Rodriguez-Porcel and L. Lowder report no disclosures relevant to the manuscript. R. Rademakers receives research support from the NIH (R01 NS080882, R01 NS076471, P50 NS072187, and P50 AG16574), the ALS Therapy Alliance, The Ed and Ethel Moore Alzheimer''s Disease Research Program, and the Consortium for Frontotemporal Degeneration Research. Dr. Rademakers received honoraria for lectures or educational activities not funded by industry; she serves on the medical advisory board of the Association for Frontotemporal Degeneration and on the board of directors of the International Society for Frontotemporal Dementia. T. Ravenscroft reports no disclosures relevant to the manuscript. B. Ghetti is supported by NIH grant P30 AG10133. M. Hagen reports no disclosures relevant to the manuscript. A. Espay is supported by NIH grant K23MH092735; has received grant support from CleveMed/Great Lakes Neurotechnologies and the Michael J Fox Foundation; has received personal compensation as a consultant/scientific advisory board member for Abbvie, Chelsea Therapeutics, TEVA, Impax, Merz, Pfizer, Acadia, Cynapsus, Solstice Neurosciences, Eli Lilly, Lundbeck, and USWorldMeds; royalties from Lippincott Williams & Wilkins and Cambridge University Press; and honoraria from UCB, TEVA, the American Academy of Neurology, and the Movement Disorders Society. He serves as Associate Editor of Movement Disorders, Frontiers in Movement Disorders, and Journal of Clinical Movement Disorders, and on the editorial boards of Parkinsonism and Related Disorders and The European Neurological Journal. Go to Neurology.org for full disclosures.",

year = "2016",

month = mar,

day = "22",

doi = "10.1212/WNL.0000000000002491",

language = "English (US)",

volume = "86",

pages = "1164--1166",

journal = "Neurology",

issn = "0028-3878",

publisher = "Lippincott Williams and Wilkins",

number = "12",

}

TY - JOUR

T1 - Fulminant corticobasal degeneration

T2 - Agrypnia excitata in corticobasal syndrome

AU - Rodriguez-Porcel, Federico

AU - Lowder, Lindsey

AU - Rademakers, Rosa

AU - Ravenscroft, Thomas

AU - Ghetti, Bernardino

AU - Hagen, Mathew C.

AU - Espay, Alberto J.

N1 - Funding Information: Disclosure: F. Rodriguez-Porcel and L. Lowder report no disclosures relevant to the manuscript. R. Rademakers receives research support from the NIH (R01 NS080882, R01 NS076471, P50 NS072187, and P50 AG16574), the ALS Therapy Alliance, The Ed and Ethel Moore Alzheimer''s Disease Research Program, and the Consortium for Frontotemporal Degeneration Research. Dr. Rademakers received honoraria for lectures or educational activities not funded by industry; she serves on the medical advisory board of the Association for Frontotemporal Degeneration and on the board of directors of the International Society for Frontotemporal Dementia. T. Ravenscroft reports no disclosures relevant to the manuscript. B. Ghetti is supported by NIH grant P30 AG10133. M. Hagen reports no disclosures relevant to the manuscript. A. Espay is supported by NIH grant K23MH092735; has received grant support from CleveMed/Great Lakes Neurotechnologies and the Michael J Fox Foundation; has received personal compensation as a consultant/scientific advisory board member for Abbvie, Chelsea Therapeutics, TEVA, Impax, Merz, Pfizer, Acadia, Cynapsus, Solstice Neurosciences, Eli Lilly, Lundbeck, and USWorldMeds; royalties from Lippincott Williams & Wilkins and Cambridge University Press; and honoraria from UCB, TEVA, the American Academy of Neurology, and the Movement Disorders Society. He serves as Associate Editor of Movement Disorders, Frontiers in Movement Disorders, and Journal of Clinical Movement Disorders, and on the editorial boards of Parkinsonism and Related Disorders and The European Neurological Journal. Go to Neurology.org for full disclosures.

PY - 2016/3/22

Y1 - 2016/3/22

UR - http://www.scopus.com/inward/record.url?scp=84961589952&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84961589952&partnerID=8YFLogxK

U2 - 10.1212/WNL.0000000000002491

DO - 10.1212/WNL.0000000000002491

M3 - Article

C2 - 26873956

AN - SCOPUS:84961589952

SN - 0028-3878

VL - 86

SP - 1164

EP - 1166

JO - Neurology

JF - Neurology

IS - 12

ER -

Fulminant corticobasal degeneration: Agrypnia excitata in corticobasal syndrome

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this